CXCR1 and breast cancer: Pre-clinical studies demonstrate that combining CXCR1/2 inhibitors with the human epidermal growth factor receptor 2 (HER2)-targeted therapies has potential as an effective treatment strategy to repress CSCs activity in breast cancer (Singh et al., 2013).